Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

• Although Hodgkin's lymphoma is a highly curable disease with modern chemotherapy protocols, some patients are primary refractory or relapse after first-line chemotherapy or even after high-dose therapy and autologous stem cell transplantation. We investigated the potential role of allogeneic stem cell transplantation in this setting.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine (hsv//eng)

Keyword

Adolescent

Adult

Europe

Female

Graft vs Host Disease

immunology

mortality

Hodgkin Disease

immunology

mortality

surgery

Humans

Male

Middle Aged

Prospective Studies

Recurrence

prevention & control

Stem Cell Transplantation

methods

mortality

Survival Rate

Transplantation Conditioning

methods

mortality

Transplantation

Homologous

mortality

Young Adult

Publication and Content Type

ref (subject category)

art (subject category)